Clinical trials: Choroidal NeoVascularization, open to volunteers
Maculopathy
AVIGA3 (Cohort 2.0)
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central…
- Trial name
- AVIGA3 (NCT07255859)
- Testing
- Amsler Grid, AVIGA
- Where
- Singapore
- Volunteers
- 60 people
- Sponsor
- Tan Tock Seng Hospital
Age Related Macular Degeneration, Diabetic Retinopathy
Effect of Video Viewing on Intravitreal Injection Experience
Study Objective The goal of this clinical trial is to evaluate whether viewing a procedural video can improve the patient experience and reduce the incidence and severity of subconjunctival hemorrhage in individuals undergoing…
- Conditions
- Age Related Macular Degeneration, Diabetic Retinopathy, Choroidal Neovascularization, Retinal Vein Occlusion
- Trial name
- NCT07002372
- Testing
- Procedure video viewing
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
The purpose of this study is to evaluate the efficacy and safety of the aflibercept 8 mg used in a personalized regimen, with flexible loading dose and treatment intervals from 8 to 24 weeks in eyes with treatment-naive PCV.
- Trial name
- PALLAS (NCT07389980)
- Testing
- aflibercept 8 mg
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
The goal of this clinical trial is to assess the efficacy, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV).
- Trial name
- MONDEGO (NCT06709339)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 31 sites in Italy, Portugal and 2 more
- Volunteers
- 120 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy
OCT in Rare Chorioretinal Diseases
This study will evaluate the total blood flow in the retina and choroid (structures in the back of the eye) by Doppler optical coherence tomography (OCT) and OCT angiography. Angiography is mapping of the blood vessels.
- Conditions
- Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia
- Trial name
- NCT02141308
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Oregon Health and Science University
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Myopic Choroidal Neovascularisation, Anti-VEGF Treatment
The Treatment Burden of Myopic Choroidal Neovascularization
Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue.
- Conditions
- Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden
- Trial name
- mCNV burden (NCT07009574)
- Testing
- anti-VEGF intravitreal treatment in patients affected by myopic choroidal neovascularization
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Policlinico Gaspare Rodolico - San Marco Catania
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Presumed Ocular Histoplasmosis
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational…
- Trial name
- PLANE (NCT07695298)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cincinnati Eye Institute, Southwest Ohio
Choroidal Neovascularization, Mineralocorticoid Excess
Biomarkers and Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
- Trial name
- BioNéoRet (NCT04439708)
- Testing
- Blood and aqueous humor biomarker of treatment response
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- TORRONTES (NCT07496567)
- Testing
- Tiespectus, Aflibercept
- Where
- 71 sites in United States, Brazil and 7 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Myopic Choroidal Neovascularization
Deep Learning-Based OCTA Quantification and Modeling for Predicting Long-Term Anti-VEGF Efficacy in mCNV
Myopic choroidal neovascularization (mCNV) is one of the sight-threatening complications secondary to pathological myopia. Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is its first-line therapy.
- Trial name
- NCT07402629
- Testing
- No interventions beyond routine medical care
- Volunteers
- 110 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
- Trial name
- HANGANG (NCT07461441)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yeungnam University College of Medicine
Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
The goal of this clinical trial is to investigate the efficacy, durability, and safety of aflibercept 8 mg in treating Polypoidal Choroidal Vasculopathy (PCV) in Chinese naive patients.
- Trial name
- NCT07365371
- Testing
- Aflibercept Intravitreous Injection
- Where
- 20 sites in China
- Volunteers
- 174 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Macular Degeneration Choroidal Neovascularization
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability…
- Trial name
- Fixed farcimab (NCT06742307)
- Testing
- Faricimab Injection [Vabysmo]
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Hospital Authority, Hong Kong
Age-related Macular Degeneration (ARMD), Choroidal Neovascularization
Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization
Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly…
- Conditions
- Age-related Macular Degeneration (ARMD), Choroidal Neovascularization, Anti-vascular Endothelial Growth Factor
- Trial name
- NCT07187804
- Testing
- Intravitreal faricimab injection
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Kim's Eye Hospital
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.